$436 Million is the total value of Invus Financial Advisors, LLC's 7 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
RCUS | Arcus Biosciences Inc | $51,726,000 | +8.2% | 1,842,077 | 0.0% | 11.86% | -40.7% | |
OYST | Oyster Point Pharma Inc | $50,610,000 | -2.9% | 2,768,586 | 0.0% | 11.60% | -46.7% | |
NVCR | Novocure Ltd | $46,380,000 | -23.6% | 350,884 | 0.0% | 10.63% | -58.1% | |
ORIC | Oric Pharmaceuticals Inc | $24,686,000 | -27.6% | 1,007,575 | 0.0% | 5.66% | -60.3% | |
UBX | Unity Biotechnology Inc | $6,570,000 | +14.5% | 1,094,998 | 0.0% | 1.51% | -37.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Arcus Biosciences Inc | 16 | Q3 2023 | 24.7% |
Novocure Ltd | 16 | Q3 2023 | 25.4% |
Oric Pharmaceuticals Inc | 14 | Q3 2023 | 14.3% |
Oyster Point Pharma Inc | 13 | Q4 2022 | 44.5% |
Coupang Inc | 11 | Q3 2023 | 51.6% |
Taboola.com Ltd | 10 | Q3 2023 | 23.7% |
Unity Biotechnology Inc | 9 | Q4 2021 | 8.0% |
Yext Inc | 8 | Q3 2021 | 30.3% |
IONQ Inc | 8 | Q3 2023 | 7.2% |
Nu Hldgs Ltd | 6 | Q3 2023 | 25.4% |
View Invus Financial Advisors, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-14 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
13F-HR | 2021-11-15 |
View Invus Financial Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.